DMA Diamedica Therapeutics

DiaMedica (TSX VENTURE:DMA) announces today that in accordance with the terms of
the warrant indenture for those warrants issued on July 22, 2011 the Company
will provide the required written notice to holders of such warrants that the
expiry date has been accelerated to the close of business September 7, 2012. 


Under the terms of the warrant indenture, if the 10-day volume weighted average
trading price of the common shares of DiaMedica on the TSX Venture Exchange
exceeds $2.00, then at any date subsequent to this date, the expiry date of the
warrant shall be the day that is 30 days following the later of (i) the date
that written notice of the accelerated expiry is sent to warrantholders; and
(ii) the date on which the announcement of the warrant expiry acceleration is
made by news release. As of the close of business on August 3, 2012, the 10-day
volume-weighted average trading price of the common shares exceeded $2.00.
Warrants may be exercised through payment of the exercise amount of $1.50 per
full warrant up to the close of business on September 7, 2012. If all of the
993,800 outstanding warrants subject to this acceleration are exercised,
DiaMedica will receive additional proceeds of $1,490,700. Any warrants not
exercised prior to the accelerated expiry date and time will expire without any
further action being taken.


About DiaMedica 

DiaMedica is a biopharmaceutical company focused on discovery and development of
novel therapeutic compounds for diabetes and other major, medically-unmet
diseases. DiaMedica's lead compound, DM-199, is a recombinant human protein that
represents a novel approach to treating Type 1 and Type 2 diabetes. In a Type 1
diabetes model, DM-199 halted the autoimmune attack on beta cells by stimulating
regulatory T-cells, and resulted in a 12-fold increase in C-peptide levels. In
Type 2 diabetes models, DM-199 treatment stimulated proliferation of insulin
producing beta cells, resulting in significant improvement in glucose control.
DiaMedica is also developing a novel monoclonal antibody, DM-204 as a treatment
for Type 2 diabetes. Chronic treatment with DM-204 in a Type 2 diabetes model
resulted in significant improvement in blood glucose control and HbA1c levels
and also significant decreases in blood pressure and serum cholesterol. 


DiaMedica's DM-199 and DM-204 were both named Windhover's "2011 Top 10
Cardiovascular/ Metabolic Projects to Watch". 


The Company is listed on the TSX Venture Exchange under the trading symbol 'DMA'. 

FORWARD-LOOKING STATEMENTS 

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Company's filings with Canadian securities regulatory authorities. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Company undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024